Tzar Labs is in the business of development of cancer prognostic and diagnostic technologies, and specializes in discovering, building and commercializing innovative tests that can contribute to a clinically meaningful difference in the detection and management of cancer. The Company has developed a first-of-its-kind non-invasive 'HrC' test (NIHT) which is the most accurate screening test for all cancer and can distinguish between non-cancer, imminent cancer and the different stages of cancer. It is also the first prognostic test for cancer. The company has a host of prestigious investors from the USA, Europe and Asia.